WO2001075154A2 - Procede de sequençage parallele d'un melange d'acides nucleiques sur une surface - Google Patents

Procede de sequençage parallele d'un melange d'acides nucleiques sur une surface Download PDF

Info

Publication number
WO2001075154A2
WO2001075154A2 PCT/EP2001/003777 EP0103777W WO0175154A2 WO 2001075154 A2 WO2001075154 A2 WO 2001075154A2 EP 0103777 W EP0103777 W EP 0103777W WO 0175154 A2 WO0175154 A2 WO 0175154A2
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
nucleic acid
nucleotide
molecules
tertiary
Prior art date
Application number
PCT/EP2001/003777
Other languages
German (de)
English (en)
Other versions
WO2001075154A3 (fr
Inventor
Achim Fischer
Original Assignee
Axaron Bioscience Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10016348A external-priority patent/DE10016348A1/de
Priority claimed from DE2000151564 external-priority patent/DE10051564A1/de
Application filed by Axaron Bioscience Ag filed Critical Axaron Bioscience Ag
Priority to AU2001254771A priority Critical patent/AU2001254771A1/en
Publication of WO2001075154A2 publication Critical patent/WO2001075154A2/fr
Publication of WO2001075154A3 publication Critical patent/WO2001075154A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation

Definitions

  • the invention relates to a method for solid-phase-supported parallel sequencing of at least two different nucleic acids contained in a nucleic acid mixture.
  • nucleic acids An important method of biological analysis is the sequence analysis of nucleic acids.
  • the exact base sequence of the DNA or RNA molecules of interest is determined here. Knowing this sequence of bases allows, for example, the identification of certain genes or transcripts, i.e. the messenger RNA molecules belonging to these genes, the detection of mutations or polymorphisms, or the identification of organisms or viruses that can be clearly identified by means of certain nucleic acid molecules ,
  • the sequencing of nucleic acids is usually carried out using the chain termination method (Sanger et al. (1977) PNAS 74, 5463-5467).
  • an enzymatic addition of a single strand to the double strand is carried out by extending a "primer" hybridized to said single strand, usually a synthetic oligonucleotide, by adding DNA polymerase and nucleotide building blocks.
  • a "primer” hybridized to said single strand usually a synthetic oligonucleotide
  • a small addition of terminating nucleotide building blocks which after their incorporation into the growing strand no longer allow any further extension, leads to the accumulation of partial strands with a known end determined by the respective terminating nucleotide.
  • the mixture of strands of different lengths thus obtained is separated by size by means of gel electrophoresis.
  • the nucleotide sequence of the unknown strand can be derived from the resulting band patterns.
  • a major disadvantage of the method mentioned is the required expenditure on instruments, which limits the achievable throughput of reactions.
  • For each sequencing reaction assuming the use of termination nucleotides labeled with four different fluorophores, at least one track on a flat gel or, when using capillary electrophoresis, at least one capillary is required.
  • the resulting effort limits the number of sequencing processes that can be processed in parallel to a maximum of 96 on the currently most modern commercially available sequencing machines.
  • a disadvantage of the SBH method is the fact that the optimal hybridization conditions for oligonucleotides cannot be predicted exactly and accordingly a large set of oligonucleotides cannot be designed which on the one hand contain all possible sequence variations with their given length and on the other hand require exactly the same hybridization conditions. Thus unspecific hybridization leads to errors in the sequence determination.
  • the SBH method cannot be used for repetitive regions of nucleic acids to be sequenced.
  • Such a strategy for expression analysis consists in the quantification of discrete sequence units. These sequence units can consist of so-called ESTs (Expressed Sequence Tags). Sufficient numbers of clones from cDNA banks. which are derived from samples to be compared with one another, identical sequences can be recognized and counted and the relative frequencies of these sequences obtained in the different samples can be compared with one another (cf. Lee et al. Proc. Natl. Acad. Sei. USA 92: 8303-8307 (1995)). Different relative frequencies of a certain sequence indicate differential expression of the corresponding transcript. However, the method described is very complex since the sequencing of many thousands of clones is already necessary for the quantification of the more common transcripts.
  • Another method for sequencing tags is to coat small spheres with nucleic acid to be sequenced in such a way that each sphere receives numerous molecules of only one nucleic acid species.
  • the method of "stepwise ligation and cleavage" is then used for sequencing, in which the nucleic acid to be sequenced is degraded base by base from an artificial linker by using a type IIS restriction enzyme and its sequence is determined in the process. So that the sequencing process can be observed and recorded, the balls used are placed in a flat cuvette which is only slightly higher than the ball diameter in order to allow the formation of a single layer.
  • the balls must be in the densest packing in the cuvette, so that there is no change in the ball arrangement during the sequencing process due to the necessary exchange of the reaction solutions or due to vibrations of the device.
  • many sequencing reactions can be carried out in a small space in this way, the arrangement in a very narrow cuvette (a few micrometers in height) has considerable disadvantages, since uniform filling of the cuvette is difficult to achieve.
  • Another disadvantage is the high level of equipment required for the method. For example, high pressures must be used so that the necessary reaction solutions can be exchanged efficiently despite the small cuvette size.
  • Another disadvantage is the slight clogging of the cuvette, which is also favored by the necessarily small dimensions of the cuvette.
  • the object of the invention is to provide a method which overcomes the disadvantages of the prior art.
  • the object is achieved according to the invention by a method for parallel sequencing of at least two different nucleic acids contained in a nucleic acid mixture, wherein
  • a surface comprising islands of nucleic acids of the same type, tertiary nucleic acids;
  • the tertiary nucleic acids are cut by type IIS restriction endonucleases; (d) one or more bases of the tertiary nucleic acids are determined;
  • Linker molecules are connected by ligation to the free ends of the tertiary nucleic acid molecules, the linker molecules having one or more recognition sites for type IIS restriction endonucleases;
  • the tertiary nucleic acids are cut again by one or more type IIS restriction endonucleases which recognize sequence segments which are shown in
  • Steps (b) and (c) or (d) and (e) can be implemented by a single process measure.
  • the sequence of steps (d), (e) and (f) depends on the cleavage characteristics of the restriction endonucleases used and can be changed in this respect (see the text below).
  • the following is a special embodiment of the method according to the invention, in which in step (a)
  • a surface is provided on which at least primer molecules of a first primer and a second primer and optionally a nucleic acid mixture comprising the nucleic acid molecules with which both primers can hybridize have been irreversibly immobilized, both primers forming a pair of primers;
  • nucleic acid molecules of the nucleic acid mixture are hybridized with one or with both primers of the same primer pair;
  • the irreversibly immobilized primer molecules are extended in a complementary manner to the opposite strand with the formation of secondary nucleic acids;
  • the surface in one of nucleic acid molecules. that are provided in a liberated form that are not bound to the surface by irreversible immobilization;
  • the secondary nucleic acids are amplified to form tertiary nucleic acids.
  • Tertiary nucleic acids in accordance with step (a) can be provided by starting from a surface to which at least a first primer and a second primer and optionally a nucleic acid mixture comprising the nucleic acid molecules. with which both primers can hybridize, have been irreversibly immobilized. Both primers form a pair of primers, so they can bind to the strand or counter strand of the nucleic acid molecules. If the nucleic acid molecules of the nucleic acid mixture are already bound to the surface, the hybridization in step (a2) can be brought about by merely heating and cooling. Otherwise, the nucleic acid molecules of the nucleic acid mixture must be brought into contact with the surface in step (a2). In this context, reference is also made to WO 00/18957. The following is a special embodiment of the method according to the invention, in which in step (a) a surface is provided on which at least one primer molecule forming at least one primer pair has been irreversibly immobilized.
  • the individual work steps to be carried out can also be configured as follows:
  • Primer molecules that form at least one pair of primers are irreversibly immobilized on a surface; • Nucleic acid molecules are hybridized with one or with both primers of the same primer pair by bringing the nucleic acid mixture into contact with the surface;
  • the secondary nucleic acids are amplified to form tertiary nucleic acids:
  • the tertiary nucleic acids are cut by type IIS restriction endonucleases so that 3 ' overhanging ends or 5 ' overhanging ends are produced; one or more bases of the overhanging ends are determined;
  • Linker molecules are connected by ligation to the free ends of the tertiary nucleic acid molecules, the linker molecules having one or more recognition sites for type IIS restriction endonucleases;
  • the tertiary nucleic acids are again cut by one or more type IIS restriction endonucleases which recognize sequence segments which have been introduced into the tertiary nucleic acids by the linker molecules; and the penultimate step and the subsequent steps are repeated until the desired sequence information has been obtained.
  • the nucleic acid mixture of step (a2) can be, for example, a library, that is to say nucleic acid molecules which have an identical sequence over long distances, but differ greatly in a partial area in the middle of the identical areas.
  • the libraries often consist of optionally linearized plasmids, into which various nucleic acid fragments have been cloned, which are to be sequenced later.
  • the nucleic acid mixture can be restriction fragments, on the sections of which linker molecules of the same sequence have been ligated. As a rule, the linkers which are bound to the 5 'end of the fragments differ from the linkers which are bound to the 3' end of the fragments.
  • sequence section of interest in the nucleic acid molecules of the nucleic acid mixture is generally surrounded by two flanking sequence sections which are essentially identical for all nucleic acid molecules, at least one of the two sequence sections preferably having a self-complementary sequence.
  • the sequence section in question has a pronounced tendency in single-strand form to form a so-called hairpin structure.
  • the primers or the primer molecules in step (a1 to a3) are single-stranded nucleic acid molecules with a length of about 12 to about 60 nucleotide building blocks and more, which are broadly suitable for use in the context of PCR. They are DNA molecules. RNA molecules or their analogs which are intended for hybridization with a nucleic acid which is complementary at least over a partial region and which, as a hybrid with the nucleic acid, represent a substrate for a Doppler strand-specific polymerase.
  • the polymerase is preferably DNA polymerase I, T7 DNA polymerase, the Klenow fragment of DNA polymerase I, polymerases. which are used in PCR or a reverse transcriptase.
  • the pair of primers in step (a2) represents a set of two primers that bind to regions of a nucleic acid that flank the target sequence of the nucleic acid to be amplified and have a "polarity" with respect to the orientation of their binding to the nucleic acid, that an amplification is possible (the 3 'terms point towards one another).
  • the nucleic acid mixture can be a plasmid library, for example, and the primers would then preferentially bind in the region of the so-called multiple cloning site (MCS), one above and one below the cloning site bind the primers to the sequence segments which correspond to the linkers which, as described above, were ligated to restriction fragments on both sides.
  • MCS multiple cloning site
  • the method according to the invention is preferably carried out with only one pair of primers, such as that in US Pat. No.
  • One of the primers of a primer pair can have a sequence which enables the formation of an intramolecular nucleic acid double hex (a so-called hairpin structure), although a region of the 3 'terminus consisting of at least 13 nucleotide units remains unpaired.
  • the surface in step (a, al and a2. A4) is the accessible surface of a plastic body.
  • the surface can have a swellable layer, for example made of polysaccharides, poly sugar alcohols or swellable silicates.
  • Irreversible immobilization means the formation of interactions with the surface described above, which are stable on an hourly scale at 95 ° C. and the usual ionic strength in the PCR amplifications of step (a5). These are preferably covalent bonds, which can also be cleavable.
  • the primer molecules in step (a) are preferably irreversibly immobilized on the surface via the 5 'termini. Alternatively, immobilization can also take place via one or more nucleotide building blocks. which lie between the terms of the primer molecule in question are immobilized, although a sequence segment of at least 13 nucleotide building blocks calculated from the 3 'terminus must remain unbound.
  • the immobilization is preferably carried out by forming covalent bonds.
  • the primers should have an average distance on the surface which at least corresponds to the maximum length with full extension of the nucleic acid molecules to be amplified or is smaller.
  • the procedure is essentially as described in US Pat. No. 5,641,658 or WO 96/04404.
  • aminolink terminal primary amino groups
  • isothiocyanate-modified glass surfaces For example, Guo et al. (Nucleic Acids Res. 22 (1994). 5456-5465) described a method of activating glass surfaces with aminosilane and phenylene diisothiocyanate and then binding 5'-amino-modified oligonucleotides to them.
  • Preferred here is the use of commercially available glass supports which are activated on the one hand for binding aminolink-modified oligonucleotides and on the other hand have a structured surface which has a greater binding capacity than a flat surface (Surmodics. Eden Prairie, Minnesota, USA).
  • secondary nucleic acid in step (a3) denotes those nucleic acid molecules which are formed by complementary extension of primer molecules, the extension being complementary to the nucleic acid molecules of step (a2) which have been hybridized with the primers.
  • the surface is made up of one of nucleic acid molecules. which are not bound to the surface by irreversible immobilization are provided in the released form [step (a4)]. If the nucleic acid molecules from step (al) have already been irreversibly immobilized on the surface in step (al), no nucleic acid molecules are generally brought into contact with the surface in step (a2). As a result, they do not need to be removed in the subsequent steps. If, in step (a2), nucleic acid molecules are brought into contact with the surface for the purpose of hybridization with the primers, for example because the nucleic acid molecules are not already on the surface in step (a1) have been irreversibly immobilized, then these can be removed in step (a4) by denaturation and washing. It is possible to remove the aforementioned nucleic acid molecules only after one or more amplification cycles of step (a5) have been completed.
  • tertiary nucleic acids denotes secondary nucleic acids and those nucleic acid molecules which are formed from the secondary nucleic acids by the polymerase chain reaction method in step (a5). It is important here that the surface and the liquid reaction space surrounding the surface are free of nucleic acids to be amplified, which are not irreversibly immobilized on the surface. As a rule, the amplification results in real islands, that is to say discrete regions on the surface which carry tertiary nucleic acids of the same type, that is to say identical or complementary nucleic acid molecules.
  • step (b) the tertiary nucleic acids are treated in such a way that the products are only connected to the surface at the 5 ′ end of a strand of a double strand (“half-sided dissolving”).
  • This can be done by the tertiary nucleic acids being cleaved, particularly by restriction with a restriction endonuclease of nucleic acid double strands on one side of the surface, while the other side remains connected to the surface, which means that the double-stranded nucleic acid is only connected to the surface via a nucleic acid strand
  • This is done by incubation with a restriction endonuclease, the recognition site of which has been integrated into a primer of the primer pair used in step (a1) or which is statistically sufficiently high at least at another location within the nucleic acid molecules, which is preferably a restriction ction endonuclease of type IIS, the interface of which lies outside the primer sequence and which produces a 3 ' overhang, a 5
  • step (b) and step (c) can be implemented by a single restriction cleavage, which is particularly preferred.
  • the restriction cut effecting the “half-sided release” can therefore take place in the area of a primer sequence, in the area adjacent to it or in the interior of the tertiary nucleic acids flanked by the primer sequences.
  • step (a) it is also possible to achieve the "half-sided detachment" in another way, for example by chemical cleavage of the bond between one of the primers of the primer pair used in step (a) and the surface. Furthermore, a measure similar to the result can be taken, in which the tertiary nucleic acid molecules are denatured and supplemented to form the double strand by providing counter-strands of tertiary nucleic acids.
  • Counterstrands of the tertiary nucleic acids can be provided, for example, by one of three measures, which are listed below: - On the one hand, in step (a) primer molecules or optionally in
  • Step (al or a2) nucleic acid molecules (of the nucleic acid mixture) with flanking sequence sections are used, which have self-complementary regions and are therefore capable of intramolecular base pairing, which is expressed in a so-called hairpin structure (see also FIG. 3: ligation of “masked hairpins "in the form of double-stranded linker molecules).
  • only one primer of a pair of primers or only one flanking sequence section of two is able to form a shark instruction to ensure that the incorporation of nucleotides takes place only on one of two complementary nucleic acid molecules, so that interference of the sequence signals of both nucleic acid molecules is excluded is.
  • the tertiary nucleic acids formed in step (a5) then, in the single-stranded state, which is brought about by removing one of the two strands under denaturing conditions, have a refolding in the form of a hairpin near their 3 'terminus.
  • the double-stranded portion of the hairpin preferably extends up to and including the last base of the 3'-
  • said hairpin can serve directly as a substrate for a polymerase used for sequencing. This can be ensured by a suitable choice of the sequence of the primer molecules or of the sequence sections flanking the nucleic acid molecules.
  • GTNs can be provided in the form of hairpins by ligation of oligonucleotides which are capable of hairpin formation and, if appropriate (but not necessarily), already in the form of hairpins for ligating gation are used (see also Fig. 2).
  • This can be done in such a way that the tertiary nucleic acids are cut in the double-stranded (ie not denatured) state and are thus separated from the surface on one side.
  • This is preferably done by incubation with a restriction endonuclease which has a recognition site in exactly one of the sequences originating from one of the two primers (primer sequences) or in a sequence adjacent to these primer sequences. After the restriction cut has taken place, a free end of the tertiary nucleic acids then protrudes into the solution space, which depending on the restriction endonuclease used has an overhanging end of a predictable sequence and to which the
  • Oligonucleotide can be hybridized and ligated.
  • An oligonucleotide which has already formed a hairpin structure, that is to say is therefore partially double-stranded, and which has an overhang complementary to the free end of the tertiary nucleic acids would be particularly suitable for this.
  • the 5 'end of the oligonucleotide can carry a phosphate group, while the 3' end of the irreversibly immobilized strand and the 5 'end of the counter strand hybridized with it Have OH group (see Fig. 2, steps 1 and 2).
  • the non-irreversibly immobilized strand becomes the tertiary
  • Oligonucleotides which are unable to form a hairpin structure to hybridize with the tertiary nucleic acids to form GTN (cf. US Pat. No. 5,798,210, FIG. 8).
  • the length of the oligonucleotides plays a minor role in the measures described.
  • the oligonucleotides will have a length of less than 100 or less than 50 nucleotide building blocks, so that one can also generally speak of nucleic acids (here: polymeric nucleotides which comprise more than three nucleotide building blocks).
  • Single-stranded oligonucleotides longer than 45 Nucleotide building blocks are difficult to handle due to unspecific interactions if they do not have a sequence that enables hairpins. By ability. Training hairpins reduces non-specific interactions through competition. If double-stranded oligonucleotides are used, then the length of the oligonucleotides hardly plays a role (see also FIG. 3).
  • tertiary nucleic acids have a double-stranded partial region which enables a strand extension on the opposite strands of the tertiary nucleic acids (GTN) by means of a DNA polymerase or reverse transcriptase.
  • each of the islands of tertiary nucleic acid molecules provided in step (a) by the polymerase chain reaction process has double strands, half over the 5 'end of one and half over the 5' end of the other Strands (namely the counter strand) are bound to the surface.
  • step (c) with a restriction endonuclease of type IIS is preferably carried out in such a way that at least part of the sequence to be determined is exposed in the form of a single-stranded overhang.
  • This overhang can be a 3 'or a 5' overhang. The latter is preferred.
  • the part of the nucleic acid molecules to be exposed by the restriction cut is in the immediate vicinity of a part of the nucleic acid molecules which is already known.
  • This already known part can, for example, if the nucleic acid mixture of step (a1 or a2) is a library of restriction fragments, be one of the restriction sites of known sequence used to produce the library.
  • One or more bases of the overhanging ends in step (d) can be determined, for example, by means of one of the following measures: The sequence is determined in I) and II) via a replenishment reaction with the aid of a nucleic acid polymerase.
  • a (single-stranded) 5 'overhang at the end of a double strand is used as a template for the 3' extension of the opposite strand by a polymerase. If the length of the single-stranded overhang is only one base, labeled nucleotides or labeled termination nucleotides such as dideoxynucleotides can be used for the primer extension. In any case, it is necessary to determine the identity of the incorporated nucleotides, which is preferably done via a fluorescent labeling group attached to the nucleotide.
  • an unambiguous sequence determination requires the use of termination nucleotides, the identification of which in turn is done by a group of molecules attached to the nucleotide.
  • the sequencing of the resulting transition preferably takes place by entsymmetricbare Abbruchnukleotide by the following steps • Extension of the 3 'end of the 5' generated -Überhangs by one nucleotide, wherein the nucleotide at the 2'-OH position or at the 3'-OH Position bears a protective group that prevents (or greatly slows down) further elongation, - the nucleotide bears a group of molecules that enables the identification of the nucleotide:
  • the protective group generally also carries a group of molecules which enables identification of the incorporated nucleotide and thus the sequencing of the growing nucleic acid strand and which leaves the nucleotide when the protective group is split off.
  • the identifying group of molecules can also be bound at another location on the nucleotide, for example at the base.
  • the molecular group can be changed by bleaching.
  • the identifying group of molecules can also be removed, for example by photochemical cleavage of a photolabile bond.
  • Nucleotide building blocks (G, A, T, C) another identifying group of molecules.
  • the four types of nucleotides can be offered simultaneously. If different or even all nucleotides carry the same identifying group, the identification step is usually to be broken down into four sub-steps in which the nucleotides of one variety (G, A.T. C) are offered separately.
  • the molecular group is, for example, a fluorophore or a chromophore.
  • the latter could have its absorption maximum in the visible or in the infrared frequency range.
  • the detection is both spatially and time-resolved, so that the islands on the surface can be sequenced by nucleic acids in parallel.
  • Other examples of the aforementioned group of molecules are biotin, digoxygenin (DIG) or dinitophenol (DNP).
  • DIG digoxygenin
  • DNP dinitophenol
  • the built-in nucleotide is not identified directly, but rather is identified indirectly by treating with fluorescence-labeled streptavidin to detect incorporated nucleotides.
  • Anti-DIG-Ig or Anto-DNP-Ig is treated.
  • Termination nucleotides allow the complete sequencing of almost any length single-stranded 5 ' overhangs by the process consisting of incorporation. Identification, deprotection (ie release of the protective group and removal of the labeling group) of the termination nucleotides is repeated until the desired one Reading range is reached or until an asynchronicity between the processes associated with sequencing occurs on identical nucleic acid molecules, which prevents the generation of uniform and clearly interpretable signals.
  • An alternative to deprotection of demolition nucleotides is to replace incorporated dideoxynucleotides by incubating the insert with a polymerase with exonuclease properties (roofreading activity) and regular nucleotide building blocks, so that a smooth strand end is formed by final filling.
  • a polymerase with exonuclease properties (roofreading activity) and regular nucleotide building blocks, so that a smooth strand end is formed by final filling.
  • one of the two linker strands is replaced by the newly synthesized strand via beach displacement.
  • the procedure can also be as under I), but a 3 'overhang is generated instead of a 5' overhang. This can be done at the 3 'overhang
  • Linker molecules with an at least partially complementary but shorter overhang are hybridized and optionally ligated so that the double strand formed from the nucleic acid molecule and linker molecule has an internal single-stranded region, a “gap” (see FIGS. 10 and 11) Primer extension then takes the form of an extension of the corresponding linker strand
  • the resulting transition can be sequenced by deprotectable termination nucleotides (see FIG. 11) and then comprises the following steps
  • nucleotide Bears protective group that prevents (or greatly slows down) further elongation, the nucleotide bears a group of molecules that enables the identification of the nucleotide; • identification of the incorporated nucleotide;
  • the backward linker strand of a linker with an overhang must be phosphorylated at its 5 ' end before the ligation.
  • deprotectable termination nucleotides by incorporating labeled dideoxynucleotides, which are then replaced by means of a /? Roo / re ⁇ ⁇ img polymerase with strand extension and strand displacement of the opposite strand (see under I)). Then cut with a type IIS enzyme to restore an overhang for the next round of sequencing.
  • the tertiary nucleic acids are dephosphorylated, so that when the relevant tertiary nucleic acid with the linker is subsequently ligated via blunt ends, a “nick”, that is to say a breakage of the sugar phosphate backbone within a nucleic acid double strand results, as is shown, for example, in FIG. 11, numbers 4 and 5.
  • sequencing can be done by ligation.
  • the sequence of the overhanging ends in step (d) will be determined by ligation of the tertiary nucleic acid with a linker which in turn has an overhang which is completely or partially complementary to the overhangs of the nucleic acid molecules to be sequenced and which identifies one or more bases of the sequencing overhangs allowed.
  • steps (d) and (e) are performed together (see Fig. 12).
  • a ligase which preferably ligates hybrid mutually complementary ends, for example DNA
  • Ligase from E. coli, to a given overhang preferably one from a selection of different linker molecules, which differ from each other in their overhang.
  • linker molecule connected to the nucleic acid molecule by ligation can be identified, for example, by one or more marker groups.
  • a first single-stranded DNA molecule can first be hybridized with the overhang of the nucleic acid molecule to be sequenced and attached by ligation, then in a next step a further second DNA that is wholly or partly complementary to the first DNA molecule -Molecule hybridized to the overhanging part of the first DNA molecule and exposed again to ligation conditions, wherein ligation only takes place in the case of a completely complementary to the opposite strand 3 ' end of said second DNA molecule.
  • the nature of the ligated second DNA molecule such as an included labeling group, allows the identification of one or more bases of the overhang to be sequenced.
  • the double-stranded region formed from the first and the second DNA molecule contains a recognition site for a type IIS restriction endonuclease.
  • the linker molecule in step (e) represents an at least partially double-stranded piece of nucleic acid.
  • the simplest way to produce a linker is by hybridizing two oligonucleotides that are complementary to one another in sections. It is also possible to use a linker that is capable of intramolecular refolding (formation of a hairpin structure).
  • the linkers preferably have an end which is capable of ligation, for example a smooth end, and an end which is not capable of ligation to the end of the fragment provided, which end can be characterized, for example, by a non-palindromic overhang or a multi-base mismatch. It is possible to provide the linker with a phosphate group at its end capable of ligation (see II). In any case, the linker should carry the recognition site for a type IIS restriction endonuclease.
  • step (f) the tertiary nucleic acids are cut again with one or more type IIS restriction endonucleases, the recognition sites of which lie in the linker molecules attached in step (e) and which produce 3 'overhanging ends or 5' overhanging ends. It is preferred here that the overhang of the tertiary nucleic acids exposed by step (f) borders directly on the region of the tertiary nucleic acids previously sequenced in step (d).
  • steps (d), (e) and (f) are repeated in any order until the desired sequence information has been obtained.
  • the order of the steps is determined by the cleavage characteristics of the type IIS restriction endonucleases used in steps (c) and (f).
  • sequence information obtained for each of the islands provided in step (a) in successive cycles, each consisting of steps (d) to (f) is combined to form sequence information related to each island, the sequence information of different islands preferably being determined in parallel becomes. If the area sequenced in a given cycle borders on the area sequenced in the previous cycle, the total reading distance results from the product of the number of cycles and the number of bases determined per cycle.
  • step (b) and / or step (c) are carried out by cleaving the tertiary nucleic acids with the aid of a restriction sendonuclease that cleaves a 5 'overhang - or in another embodiment - creates a 3' overhang.
  • primer or nucleic acid molecules with flanking sequence sections are used in step (a1), of which at least one primer of a primer pair has at least one restriction site and one of these restriction sites is used for the above-mentioned restriction cleavage.
  • step (d) of the method according to the invention can be configured by the following steps:
  • nucleotide (dl) Extension of the 3 'end of the 5' overhang generated by one nucleotide, the nucleotide having a protective group at the 2'-OH position or at the 3'-OH position which prevents further extension (or greatly slowed down).
  • the nucleotide carries a group of molecules which enables the identification of the nucleotide;
  • steps (dl) to (d3) are repeated until the overhang is filled.
  • steps (dl) to (d3) are repeated until the overhang is filled.
  • a linker is ligated over smooth ends, as is described in FIG. 9.
  • step (d) is carried out by the following steps:
  • the nucleotide carries a group of molecules that enables the identification of the nucleotide
  • step (f) one or more restriction cleavages are carried out using a type IIS restriction endonuclease, which recognize sequence sections which were introduced into the tertiary nucleic acids by the linker molecules in step (e).
  • step (g) steps (e), (d) and (f) are repeated in this order until the desired sequence information has been obtained.
  • the primer molecules are irreversibly immobilized in step (a1) by forming a covalent bond to a surface.
  • step (d2) the base carries the molecular group which enables the nucleotide to be identified.
  • the nucleotide at the 3′-OH position bears the protective group in step (dl).
  • step (dl) the nucleotide at the 2'-OH position bears the protective group.
  • the protective group in step (dl) has a cleavable silyl ether, ester. Ether. Anhydride or peroxide group or an oxygen-metal group.
  • the protective group is removed in step (d3) by a complex-forming ion, preferably by cyanide.
  • a complex-forming ion preferably by cyanide.
  • the protective group is split off photochemically in step (d3).
  • the protective group has a fluorophore in step (dl) and the nucleotide is identified fluorometrically in step (d2).
  • steps (d) and (e) are implemented by the ligation of identifiable linkers to the tertiary nucleic acids.
  • This embodiment is described under III).
  • the base sequence is determined using the specificity of the ligase.
  • the base sequence is inferred from the nature of the ligation products.
  • a device is further provided with the following components:
  • At least one light source to excite fluorophores used for marking At least one light source to excite fluorophores used for marking
  • At least one photodetector for measuring the emitted fluorescence radiation At least one photodetector for measuring the emitted fluorescence radiation
  • At least one vessel for reaction solutions and waste is provided.
  • an electronic computer which stores the measured fluorescence intensity as a function of the position on the surface and, if necessary, processes the data records thus obtained.
  • the reaction chamber contains the surface on which the described processes for sequencing and possibly previously for amplification take place.
  • said surface can simultaneously serve as a wall, preferably as the upper or lower wall, of the reaction chamber.
  • the chamber for observing the processes taking place on the surface must be at least partially transparent.
  • the reaction chamber is preferably designed to be temperature-controllable, for example by means of a Peltier element. It is particularly preferred here to provide the reaction chamber with a temperature control by methods known per se which, in terms of tolerance and response behavior and other criteria, meets the high requirements of the solid-phase polymerase chain reaction (see step e) in order to include all process steps of the process according to the invention to be able to carry out only one apparatus.
  • the reaction chamber has at least one inlet and one outlet through which used or no longer required reaction solution can be exchanged for fresh or another solution.
  • Inlet and outlet are usually through suitable hose or pipe lines with one or more storage vessels or waste containers. ß connected, which serve to hold fresh or used solutions and which in turn can be temperature controlled.
  • the apparatus described preferably has at least one device for conveying liquids, which can be designed, for example, as a peristaltic pump and is used to exchange solutions.
  • the lumen of the reaction chamber is given a shape which favors the most efficient solution exchange possible.
  • the light source preferably emits monochromatic light of a wavelength which is as close as possible to the absorption maximum of the fluorophore or fluorophores used for sequencing.
  • Lasers of a suitable wavelength are preferred for this, but other light sources, for example mercury vapor lamps, can also be used.
  • the device for scanning the surface located in the reaction chamber can be designed as an XY table which carries the reaction chamber and moves perpendicular to the direction of irradiation, so that the entire area of said surface can be scanned.
  • the photodetector should have a sensitivity suitable for detecting the emitted fluorescent radiation, and on the other hand should allow a reliable differentiation when different fluorophores are used at the same time.
  • photomultipliers or avalanche diodes are suitable. which may be preceded by suitable optical filters or beam splitters for masking out undesired radiation.
  • said computer first generates a "horizontal" data set for each individual sequencing step, consisting of the identification of one base per "island" of identical tertiary nucleic acid molecules, which correlates fluorescence intensity and, if appropriate, detected wavelength and or fluorescence lifetime and position , After recording the desired number of horizontal data records, corresponding to the desired reading distance, the generation of a "vertical" data record is further preferred, in that each position of the horizontal data records, sequencing step by sequencing step, the fluorescence intensity measured at this position as well as any detected wavelength and or fluorescence life. duration is assigned. Finally, it is preferred to translate vertical data sets obtained in this way using the sequencing protocol and the fluorophores used for labeling into sequence information of the individual islands.
  • the invention further relates to the solid-phase-coupled libraries of nucleic acid molecules produced by the process according to the invention.
  • FIG. 1 shows the amplification of individual nucleic acid molecules by means of surface-bound primers to form islands of identical amplified nucleic acid molecules; 2 shows the sequencing of surface-bound amplification products; 3 shows the provision of counter-strands of tertiary nucleic acids by forming a hairpin structure in sequence sections which originate from linkers;
  • 5 shows the assembly of the detection and identification results into connected sequences
  • 6 shows the provision of primary nucleic acids for use in expression analysis
  • FIG. 7 shows the provision of primary nucleic acids for sequencing genomic clones;
  • FIG. 8 shows the result of the amplification of individual nucleic acid molecules according to FIG. 1;
  • Fig. 13 A device for performing parallel sequencing
  • 1 shows the amplification of individual nucleic acid molecules by means of surface-bound primers to form islands of identical amplified nucleic acid molecules, in particular 1 the irreversible immobilization of oligonucleotides forming a primer pair,
  • Figure 2 illustrates the sequencing of surface-bound amplification products.
  • FIG. 3 shows the provision of a GTN by forming a hairpin structure in sequence sections from which the linkers originate.
  • the nucleic acid to be sequenced (restriction fragment with two different ends, one of which is generated by the restriction endonuclease Nlal ⁇ l) is grayed out.
  • CATG overhang generated by restriction endonuclease ⁇ lll
  • GCATGC recognition site for restriction endonuclease Sphl (contains the recognition site for ⁇ lll, CATG)
  • NNNNNN NNN and MMMMMMMM "inverted repeats" (mutually complementary sequences that allow intramolecular refolding of a single strand)
  • XXXXX and YYYYY spacer region to the surface.
  • FIG. 1 shows the attachment of a sequencing primer, installation of the first termination nucleotide and parallel detection and identification of the first nucleotide building block in each case,
  • 7 shows a cDNA fragment flanked by two different linkers (L1, L2). 7 shows the provision of primary nucleic acids for sequencing genomic clones, in detail
  • FIG. 1 shows a restriction section of a genomic clone in parallel with two different restriction endonucleases (RE1-4), ligation of different linkers (L 1-4);
  • FIG. 10 shows a further alternative sequencing of surface-bound amplification products by means of termination nucleotides and restriction endonucleases of type IIS, in detail 1 the ligation of a linker molecule to a 3 " overhang which contains a recognition site (shaded) for a type IIS restriction endonuclease;
  • 11 shows a further alternative sequencing of surface-bound amplification products by means of deprotectable termination nucleotides and restriction endonucleases of type IIS, in detail
  • FIG. 12 shows a further alternative sequencing of surface-bound amplification products by means of fluorescence-coded linkers with an overhanging end and restriction endonucleases of type IIS, in detail
  • the pellet was dissolved in a restriction mixture consisting of 15 ⁇ l 10X universal buffer, 1 ⁇ l Mbol and 84 ⁇ l H 2 O and the reaction was incubated at 37 ° C. for 1 hour. It was extracted with phenol, then with chloroform and precipitated with ethanol.
  • the pellet was prepared in a ligation mixture from 0.6 ⁇ l lOx ligation buffer (Röche Molecular Biochemicals), 1 ⁇ l 10 mM ATP (Röche Molecular Biochemicals), 1 ⁇ l linker ML2025 (produced by hybridization of oligonucleotides ML20 (5 ' -TCACATGCTAAGTCTCGCGA-3') and LM25 (5 -GATCTCGCGAGACTTAGC ATGTGAC-3 ' ), ARK), 6.9 ⁇ l H 2 O and 0.5 ⁇ l T4 DNA ligase (Röche Molecular Biochemicals) dissolved and the ligation carried out overnight at 16 ° C.
  • the ligation reaction was made up to 50 ⁇ l with water, extracted with phenol, then with chloroform and, after adding 1 ⁇ l glycogen (20 mg / ml, Röche Molecular Biochemicals), with 50 ⁇ l 28% polyethylene glycol 8000 (PromegaVlO mM MgCl 2) .
  • the pellet was precipitated was washed with 70% ethanol and taken up in 100 ul water.
  • Lyophilized oligonucleotides Amino-M13rev (5'-amino-CAGGAAACAGCGATGAC-3 ' ) and Amino-T7 (5'-amino-TAATACGACTCACTATAGG-3') (ARK Scientific GmbH, Darmstadt) were lyophilized at their 5 'end carrying amino link groups added to a final concentration of 1 mM in 100 mM sodium carbonate buffer pH 9.
  • Microscope slides made of glass (“Slides”; neoLab Migge Labor at-Vertriebs GmbH, Heidelberg) were cleaned in chromosulfuric acid for 1 hour and then washed 4x with distilled water.
  • the slides were for 15 minutes in a blocking solution heated to 50 ° C. (50 mM ethanolamine (“Fluka”: Sigma Aldrich Chemie GmbH, Seelze), 0.1 M Tris pH 9 (“Fluka”: Sigma Aldrich Chemie GmbH. Seelze), 0.1% SDS (“Fluka”: Sigma Aldrich Chemie GmbH, Seelze).
  • a blocking solution heated to 50 ° C.
  • 50 mM ethanolamine (“Fluka”: Sigma Aldrich Chemie GmbH, Seelze)
  • 0.1 M Tris pH 9 (“Fluka”: Sigma Aldrich Chemie GmbH. Seelze”
  • 0.1% SDS 0.1% SDS
  • the slides were heated at 50 ° C. for 15 minutes blocked blocking solution (50 mM ethanolamine ("Fluka”: Sigma Aldrich Chemie GmbH, Seelze). 0.1 M Tris pH 9 ("Fluka”: Sigma Aldrich Chemie GmbH, Seelze). 0.1% SDS (“Fluka”: Sigma Aldrich Chemie GmbH. Seelze) treated.
  • blocked blocking solution 50 mM ethanolamine
  • 0.1 M Tris pH 9 (“Fluka”: Sigma Aldrich Chemie GmbH, Seelze).
  • 0.1% SDS (“Fluka”: Sigma Aldrich Chemie GmbH. Seelze) treated.
  • the slides were placed in 800 ml 0.1 x SSC / 0.1% SDS for 5 minutes (cf. Ausubel et al., Current Protocols in Molecular Biology (1999), John Wiley & Sons). The slides were washed with deionized water and air dried.
  • Example 4 Plasmids pRNODCAB (contains bases 982 to 1491 of the transcript of rat ornithine decarboxylase, AC number J04791, cloned into vector pCR II (Invitrogen BV, Groningen, the Netherlands) and pRNHPRT (contains bases 238 to 720 of the transcript Hypo Rat xanthine phosphoribosyl transferase, AC number M63983, cloned in vector pCR II (Invitrogen)) were linearized by adding 1 ⁇ g plasmid in a volume of 20 ⁇ l lx restriction buffer H (“Röche Molecular Biochemicals”: Röche Diagnostics GmbH, Mannheim) with each 5 U of the restriction enzymes BgHl and Seal (Röche Molecular Biochemicals) were incubated for 1.5 hours at 37 ° C.
  • the vector inserts were then amplified by adding 1 ⁇ l of the restriction mixtures in a volume of 100 ⁇ l PCR buffer II (Perkin-Elmer, Foster City, California, USA) with 4 ⁇ l 10 mM primer T7 (5'-TAATACGACTCACTATAGG-3 ' ), 4 ⁇ l 10 mM primer M13 (5 ' - CAGGAAACAGCGATGAC-3 ') (ARK), 4 ⁇ l 50 mM MgCl 2 ("Fluka”: S igma Aldrich Chemie GmbH, Seelze), 5 ⁇ l dimethyl sulfoxide (“Fluka”: Sigma Aldrich Chemie GmbH, Seelze), 1 ⁇ l 10 mM dNTPs (Röche Molecular Biochemicals), and 1 ⁇ l AmpliTaq DNA Polymerase (5u ⁇ l; Perkin-Elmer) was transferred.
  • PCR buffer II Perkin-Elmer, Foster City, California, USA
  • 4 ⁇ l 10 mM primer T7 5
  • the reactions were then subjected in a Gene Amp 9700 thermal cycler (Perkin-Elmer) to a temperature program consisting of 20 cycles of denaturation for 20 seconds at 95 ° C, primer annealing for 20 seconds at 55 ° C and primer extension for 2 minutes at 72 ° C.
  • the amplification products were examined electrophoretically on a 1.5% agarose gel for their correct size.
  • the reactions were purified using QiaQuick columns (Qiagen AG, Hilden) according to the manufacturer's instructions and eluted in 50 ⁇ l deionized water.
  • Amplification In order to attach the nucleic acids prepared in Example 2 to glass supports, annealing mixtures of 1 .mu.l undiluted or in parallel batches 1:10, 1: 100 or 1: 1000 amplification product solutions diluted with water, 4 .mu.l 50 mM each MgCL solution, 1 ⁇ l bovine serum albumin (20 mg / ml: Röche Molecular Biochemicals), 5 ⁇ l dimethyl sulfoxide, 1 ⁇ l 10 mM dNTPs and 1 ⁇ l AmpliTaq each in a total volume of 100 ⁇ l lx PCR buffer II.
  • the following temperature program was used for the annealing and the subsequent primer extension: denaturation for 30 seconds at 94 ° C, annealing for 10 minutes at 55 ° C, primer extension for 1 minute at 72 ° C.
  • the reaction chambers were removed and the slides were rinsed with deionized water.
  • the mixture was boiled in 800 ml of 0.1 ⁇ SSC / 0.1% SDS for 1 minute, the slides were rinsed with water and air-dried.
  • reaction chambers were again applied at the previously selected positions and 65 ⁇ l of an amplification mixture were applied, composed as follows: 4 ⁇ l 50 mM MgCl 2 , 1 ⁇ l bovine serum albumin (20 mg / ml) , 5 ul dimethyl sulfoxide. 1 ⁇ l AmpliTaq (5 U / ⁇ l), 1 ⁇ l 10 mM dNTPs, in 100 ⁇ l lx PCR buffer II.
  • the following temperature program was applied to the in situ thermocycler: denaturation at 93 ° C for 20 seconds, Primerannealing 20 seconds at 55 ° C, extension 1 minute at 72 ° C, for 50 cycles.
  • the chambers were removed and the slides rinsed with water and air dried.
  • SYBR Green I solution (Molecular Probes: solution 1: 10,000 in water) were pipetted onto the slides and covered with cover glasses # 2 (MJ). Detection was carried out on a DMRBE confocal microscope (Leica Microsystems Heidelberg GmbH, Heidelberg) with an excitation wavelength of 488 nm and a detection wavelength of 530 nm.
  • Example 6 To identify the nucleic acid molecules in the detected clonal islands, the slides were decolorized in water for 10 minutes after detection of the double-stranded DNA stained with SYBR Green. Reaction chambers were then stuck on again at the same positions as before and a restriction mixture consisting of 12 ⁇ l lOx universal buffer (Stratagene GmbH, Heidelberg), 1 ⁇ l bovine serum albumin, 3 ⁇ l restriction tion endonuclease Mbol (1 U / ⁇ l; Stratagene) and 64 ⁇ l water, pipetted in. To restrict the nucleic acid molecules by means of the internal bol interface, incubation was carried out at 37 ° C. for 1.5 h, then the reaction chambers were removed and the slides were washed with water.
  • a restriction mixture consisting of 12 ⁇ l lOx universal buffer (Stratagene GmbH, Heidelberg), 1 ⁇ l bovine serum albumin, 3 ⁇ l restriction tion endonuclease Mbol (1 U / ⁇ l; Stratagen
  • strand fragments which were not covalently bound to the glass support were removed by denaturation for 2 minutes in 800 ml of boiling 0.1 ⁇ SSC / 0.1% SDS. After washing again in water and air drying, new reaction chambers were applied.
  • a hybridization solution consisting of 8 ⁇ l 10 x PCR buffer II, 3.2 ⁇ l 50 mM MgCl 2 , 2 ⁇ l 100 pmol / ⁇ l oligonucleotide probe Cy5-HPRT (5'-Cy5-TCTACAGTCATAGGAATGGACCTATCACTA-3 ' ; ARK), 2 ⁇ l 100 was used pmol / ul oligonucleotide probe Cy3-ODC (5 ' -Cy3-ACATGTTGGTCCCCAGATGCTGGA-TGAGTA-3') and 65 ul water.
  • Example 2 Expression Analysis by Highly Parallel Sequencing of Nucleic Acid Molecules
  • the ligation products obtained in Example 1 were diluted 1: 1000 with water and 1 ⁇ l of this dilution was amplified in a compartment as described in Example 5 for 50 cycles. Glass slides coated with the amplification primers amino-CP28V (5 ' - amino-ACCTACGTGCAGATTTTTTTTTTTTTTTV-3') and amino-ML20 (5'-amino-TCACATGCTAAGTCTCGCGA-3 ' ) were used for this as described.
  • the amplification mixture was replaced by a restriction mixture consisting of 12 ⁇ l 10 ⁇ Universal buffer (Stratagene), 1 ⁇ l bovine serum albumin, 4 ⁇ l restriction endonuclease Mbol. in a final volume of 65 ⁇ l. After incubation at 37 ° C. for 2 h, the restriction mixture was replaced by a dephosphorylation mixture of 1 U alkaline phosphatase from arctic crabs (Amersham) in 65 ⁇ l of the reaction buffer supplied. After incubation for 1 hour at 37 ° C.
  • reaction chambers and the dephosphorylation mixture were removed, the slides were washed thoroughly with distilled water, reaction chambers were applied again and filled with 65 ⁇ l of a ligation mixture consisting of 3 U T4 DNA ligase (Röche Diagnostics) and 500 ng am 5 "end of phosphorylated Hai ⁇ in sequencer SLP33 (5 ' -TCTTCGAATGCACTG-AGCGCATTCGAAGATC-3') in 65 ⁇ l of the supplied ligation buffer. It was ligated for 14 hours at 16 ° C., then the ligation mixture and reaction chambers were removed.
  • dATP, dCTP, dGTP and dTTP were treated for 2 minutes in 800 ml boiling 0.1x SSC / 0.1% SDS and washed with distilled water.
  • suitable deprotectable nucleotides dATP, dCTP, dGTP and dTTP (Röche Molecular Biochemicals) were used on their 3rd '-OH group esterified with 4-aminobutyric acid These derivatives were labeled with the fluorescent groups FAM (dATP, dCTP) and ROX (dGTP, dTTP) (Molecular Probes Inc., Eugene, Oregon, USA) for the parallel determination of the first base Reaction chambers were again applied to the slides and a primer extension mixture of 1 mM FAM-dATP, 1 mM ROX-dGTP and 2 U Sequenase (United States Biochemical Co ⁇ ., Cleveland, Ohi o, USA) in 65 ⁇ l reaction buffer (40 mM Tris-HCl pH 7.5,
  • Microscope slides (Merck Eurolab GmbH, Darmstadt) were cleaned with ethanol and treated with binding silane (Amersham Pharmacia Biotech GmbH. Freiburg; 50 ⁇ l silane and 50 ⁇ l acetic acid in 10 ml ethanol). After removing excess silane by means of ethanol and wipes, an acrylamide polymerization mixture was prepared, consisting of 10 ⁇ l 50% “long range” acrylamide solution (Biozym Diagnostik GmbH, Hessisch Oldendorf), each 20 ⁇ l 200 ⁇ M acrydite-modified primer Acryl-T ⁇ 5 - T7 (5 ' -Acrydite-TTT TTT TTT TTT TTT AAT ACG ACT CAC TAT AGG-3'; Eurogen- tec, Seraing / Belgium) and Acryl-TA, 5 -M13 (5 '-Acrydite- TTA TTA TTA TTA TTA CAG GAA ACA GCG ATG AC-3 '; Eurogentec).
  • a primer binding solution was prepared, consisting of 19 mg l-ethyl-3- (3-dimethylaminopropyl) carbodiimide (Sigma-Aldrich Chemie GmbH, Steinheim), 100 ⁇ l 1 M 1 -methylimidazole (Sigma-Aldrich), each 20 ⁇ l 100 ⁇ M amino-modified primer Amino-T ⁇ 5 -T7 (5'-Amino-TTT TTT TTT TTT TTT TTT AAT ACG ACT CAC TAT AGG-3 '; ARK) and Amino-TA ⁇ 5 -M13 (5 ' -Amino- TTA TTA TTA TTA TTA CAG GAA ACA GCG ATG AC-3 ': ARK).
  • Nucleic acid molecules were prepared analogously to Example 1, except that BL2123 (produced by hybridization of the oligonucleotides BL23 [5 '- GCTCAGATCGCAGCTTAGCGAT-3'] and LB 21 [5'-
  • the amplification products thus obtained were incubated with a restriction mixture consisting of 10 U restriction endonuclease Bbvl (New England Biolabs) and 1 ⁇ l bovine serum albumin in 65 ⁇ l lx NEBuffer 2 (New England Biolabs) for 1 h at 37 ° C. to detach the amplification products from the support.
  • a restriction mixture consisting of 10 U restriction endonuclease Bbvl (New England Biolabs) and 1 ⁇ l bovine serum albumin in 65 ⁇ l lx NEBuffer 2 (New England Biolabs) for 1 h at 37 ° C.
  • the slides were distilled Washed water and provided with new glass reaction chambers, which had a lumen of 150 ⁇ l and had two closable openings for exchanging solutions.
  • the first base of the 5 'overhang produced was determined by inco-fluorescence-labeled, deprotectable termination nucleotides and the protective group was then removed.
  • a ligation mixture consisting of 10 U T4 DNA ligase (Röche) and 3 ⁇ g of the Rbvl linker BL2123P was applied in 150 ⁇ l to 1 mM hexamine cobalt (III) chloride (Fluka). 0.3 mM ATP and 0.5 mM spermidine trihydrochloride (Sigma-Aldrich) supplemented ligase buffer.
  • the Rbvl linker BL2123P was previously prepared by hybridizing the oligonucleotides BL23 (5'-GCTCAGATCGCAGCTTAGCGAT-3 '; ARK) and LB21P (5'-ATCGCTAAGCTGCGATCTGA-3'; 5 ' -phosphorylated; ARK) in ligase buffer. After ligation for 8 hours at 16 ° C., Bbvl was cut again as described above, the chambers were rinsed thoroughly and the overhangs were sequenced. This process of sequencing, linker ligation and renewed generation of an overhang shifted towards the inside of the fragment via Rbvl restriction was repeated three more times, so that a reading range of 20 bases in total was achieved.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de séquençage parallèle d'au moins deux acides nucléiques différents contenus dans un mélange d'acides nucléiques, comprenant les opérations suivantes: préparer une surface comportant des îlots d'acides nucléiques, dans chaque cas de même sorte, des acides nucléiques tertiaires; traiter les acides nucléiques tertiaires de telle sorte que les produits sont en liaison avec la surface seulement par l'extrémité 5' d'un double brin ; couper les acides nucléiques tertiaires avec des endonucléases de restriction de type IIS de sorte à donner naissance à des extrémités 3' ou 5' en saillie ; déterminer une ou plusieurs bases des acides nucléiques tertiaires; relier par ligature des molécules de liaison avec les extrémités libres des molécules d'acide nucléique tertiaire, ces molécules de liaison présentant une ou plusieurs marques témoignant des endonucléases de restriction de type IIS; couper à nouveau les acides nucléiques tertiaires avec une ou plusieurs endonucléases de restriction de type IIS, qui reconnaissent les parties de séquences introduites à l'étape (e) par les molécules de liaison dans les acides nucléiques tertiaires ; réitérer les étapes (d), (e) et (f) jusqu'à ce que l'information de séquence voulue soit obtenue.
PCT/EP2001/003777 2000-04-03 2001-04-03 Procede de sequençage parallele d'un melange d'acides nucleiques sur une surface WO2001075154A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001254771A AU2001254771A1 (en) 2000-04-03 2001-04-03 Novel method for the parallel sequencing of a nucleic acid mixture on a surface

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10016348A DE10016348A1 (de) 2000-04-03 2000-04-03 Verfahren zur Erzeugung und parallelen Sequenzierung einer Bibliothek von Nukleinsäuremolekülen an einer Oberfläche
DE10016348.3 2000-04-03
DE10051564.9 2000-10-18
DE2000151564 DE10051564A1 (de) 2000-10-18 2000-10-18 Neue Verfahren zur parallelen Sequenzierung eines Nukleinsäuregemisches an einer Oberfläche

Publications (2)

Publication Number Publication Date
WO2001075154A2 true WO2001075154A2 (fr) 2001-10-11
WO2001075154A3 WO2001075154A3 (fr) 2003-01-03

Family

ID=26005149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/003777 WO2001075154A2 (fr) 2000-04-03 2001-04-03 Procede de sequençage parallele d'un melange d'acides nucleiques sur une surface

Country Status (2)

Country Link
AU (1) AU2001254771A1 (fr)
WO (1) WO2001075154A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006040104A3 (fr) * 2004-10-09 2006-07-20 Achim Fischer Sequençage d'acides nucleiques par deplacement de brin
US7645596B2 (en) 1998-05-01 2010-01-12 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US7666593B2 (en) 2005-08-26 2010-02-23 Helicos Biosciences Corporation Single molecule sequencing of captured nucleic acids
US7981604B2 (en) 2004-02-19 2011-07-19 California Institute Of Technology Methods and kits for analyzing polynucleotide sequences
EP2426214A1 (fr) * 2010-09-01 2012-03-07 Koninklijke Philips Electronics N.V. Procédé pour amplifier des acides nucléiques
US9096898B2 (en) 1998-05-01 2015-08-04 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9657344B2 (en) 2003-11-12 2017-05-23 Fluidigm Corporation Short cycle methods for sequencing polynucleotides
WO2022144003A1 (fr) * 2020-12-31 2022-07-07 东科智生基因科技（北京）有限公司 Procédé de construction d'une bibliothèque pcr multiplex pour séquençage ciblé à haut débit

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006678A1 (fr) * 1989-10-26 1991-05-16 Sri International Sequençage d'adn
WO1993005183A1 (fr) * 1991-09-09 1993-03-18 Baylor College Of Medicine Procede et dispositif pour la determination rapide du sequençage d'adn ou d'arn au moyen d'une methode de sequençage par addition de base
US5547839A (en) * 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5641658A (en) * 1994-08-03 1997-06-24 Mosaic Technologies, Inc. Method for performing amplification of nucleic acid with two primers bound to a single solid support
US6013445A (en) * 1996-06-06 2000-01-11 Lynx Therapeutics, Inc. Massively parallel signature sequencing by ligation of encoded adaptors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547839A (en) * 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
WO1991006678A1 (fr) * 1989-10-26 1991-05-16 Sri International Sequençage d'adn
WO1993005183A1 (fr) * 1991-09-09 1993-03-18 Baylor College Of Medicine Procede et dispositif pour la determination rapide du sequençage d'adn ou d'arn au moyen d'une methode de sequençage par addition de base
US5641658A (en) * 1994-08-03 1997-06-24 Mosaic Technologies, Inc. Method for performing amplification of nucleic acid with two primers bound to a single solid support
US6013445A (en) * 1996-06-06 2000-01-11 Lynx Therapeutics, Inc. Massively parallel signature sequencing by ligation of encoded adaptors

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096898B2 (en) 1998-05-01 2015-08-04 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US7645596B2 (en) 1998-05-01 2010-01-12 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US10214774B2 (en) 1998-05-01 2019-02-26 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US10208341B2 (en) 1998-05-01 2019-02-19 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9957561B2 (en) 1998-05-01 2018-05-01 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9725764B2 (en) 1998-05-01 2017-08-08 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9458500B2 (en) 1998-05-01 2016-10-04 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9212393B2 (en) 1998-05-01 2015-12-15 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9657344B2 (en) 2003-11-12 2017-05-23 Fluidigm Corporation Short cycle methods for sequencing polynucleotides
US7981604B2 (en) 2004-02-19 2011-07-19 California Institute Of Technology Methods and kits for analyzing polynucleotide sequences
WO2006040104A3 (fr) * 2004-10-09 2006-07-20 Achim Fischer Sequençage d'acides nucleiques par deplacement de brin
US9868978B2 (en) 2005-08-26 2018-01-16 Fluidigm Corporation Single molecule sequencing of captured nucleic acids
US7666593B2 (en) 2005-08-26 2010-02-23 Helicos Biosciences Corporation Single molecule sequencing of captured nucleic acids
CN103221552B (zh) * 2010-09-01 2015-09-30 皇家飞利浦电子股份有限公司 用于扩增核酸的方法
US9005896B2 (en) 2010-09-01 2015-04-14 Koninklijke Philips N.V. Method for amplifying nucleic acids
CN103221552A (zh) * 2010-09-01 2013-07-24 皇家飞利浦电子股份有限公司 用于扩增核酸的方法
WO2012029037A1 (fr) * 2010-09-01 2012-03-08 Koninklijke Philips Electronics N.V. Procédé d'amplification d'acides nucléiques
EP2426214A1 (fr) * 2010-09-01 2012-03-07 Koninklijke Philips Electronics N.V. Procédé pour amplifier des acides nucléiques
WO2022144003A1 (fr) * 2020-12-31 2022-07-07 东科智生基因科技（北京）有限公司 Procédé de construction d'une bibliothèque pcr multiplex pour séquençage ciblé à haut débit

Also Published As

Publication number Publication date
WO2001075154A3 (fr) 2003-01-03
AU2001254771A1 (en) 2001-10-15

Similar Documents

Publication Publication Date Title
EP1244782A2 (fr) Procede de sequen age parallele d'un melange d'acides nucleiques sur une surface
DE69434066T2 (de) Verfahren zur immobilisierung von nukleinsäuremolekülen
DE69432919T2 (de) Verfahren für den Nachweis spezifischer Polynukleotiden
DE60029961T2 (de) Verankerte strangverdrängungs-amplifizierung auf einem elektronisch adressierbaren mikrochip
DE60208278T2 (de) System und Verfahren zum Testen von Nukleinsäuremolekülen
DE60114525T2 (de) Array-basierende Methoden zur Synthese von Nukleinsäuregemischen
DE69924140T2 (de) Bestimmung der länge von repetitiven nukleinsäure-sequenzen durch eine diskontinuierliche primerverlängerung
EP0718408A2 (fr) Méthode sensible pour détecter des acides nucléiques
DE10120798A1 (de) Verfahren zur Bestimmung der Genexpression
DE10214395A1 (de) Verfahren zur Analyse von Einzelnukleotidpolymorphismen
DE102004025695A1 (de) Verfahren und Oberfläche zur parallelen Sequenzierung von Nukleinsäureketten
DE102004025694A1 (de) Verfahren und Oberfläche zu hochparallelen Analysen von Nukleinsäureketten
DE102004025745A1 (de) Oberfläche für die Analysen an einzelnen Molekülen
DE102004025744A1 (de) Oberfläche für die Analysen an einzelnen Nukleinsäuremolekülen
DE102006014879A1 (de) RNA-Markierungsverfahren
DE10253966B4 (de) Microarray-basiertes Verfahren zur Amplifikation und Detektion von Nukleinsäuren in einem kontinuierlichen Prozess
WO2001075154A2 (fr) Procede de sequençage parallele d'un melange d'acides nucleiques sur une surface
WO2008110622A1 (fr) Procédé et kit de test permettant la détection rapide de séquences d'acides nucléiques spécifiques, notamment la détection de mutations ou de polymorphismes d'un seul nucléotide (snp)
EP1453975B1 (fr) Procede de mise en evidence de processus d'hybridation dans des acides nucleiques
DE102018103215B3 (de) Verfahren und Vorrichtung zur Extraktion einer Nukleinsäure aus einer Probenflüssigkeit
DE10051564A1 (de) Neue Verfahren zur parallelen Sequenzierung eines Nukleinsäuregemisches an einer Oberfläche
WO2013045417A1 (fr) Analyse d'acides nucléiques spécifique à une séquence
DE60017750T2 (de) Amplifizierungsverfahren zum Nachweis von zu bestimmenden Nucleinsäuren und Anwendung von Flourszenzenergieübertragung
DE10016348A1 (de) Verfahren zur Erzeugung und parallelen Sequenzierung einer Bibliothek von Nukleinsäuremolekülen an einer Oberfläche
DE102011056606B3 (de) Verfahren zur elektrochemischen Detektion von Nukleinsäureoligomer-Hybridisierungsereignissen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP